A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist
R Bosch, M Petrone, R Arends, P Vicini… - CPT …, 2022 - Wiley Online Library
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) and dual GLP‐
1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in …
1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in …
The effects of a GLP‐1 analog on glucose homeostasis in type 2 diabetes mellitus quantified by an integrated glucose insulin model
RM Røge, S Klim, SH Ingwersen… - CPT …, 2015 - Wiley Online Library
In recent years, several glucagon‐like peptide‐1 (GLP‐1)‐based therapies for the treatment
of type 2 diabetes mellitus (T2DM) have been developed. The aim of this work was to extend …
of type 2 diabetes mellitus (T2DM) have been developed. The aim of this work was to extend …
A generic integrated physiologically based whole‐body model of the glucose‐insulin‐glucagon regulatory system
Models of glucose metabolism are a valuable tool for fundamental and applied medical
research in diabetes. Use cases range from pharmaceutical target selection to automatic …
research in diabetes. Use cases range from pharmaceutical target selection to automatic …
A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin
N Wu, G An - Journal of pharmaceutical sciences, 2024 - Elsevier
In the current study, we established a comprehensive quantitative systems pharmacology
(QSP) model using linagliptin as the model drug, where drug disposition, drug intervention …
(QSP) model using linagliptin as the model drug, where drug disposition, drug intervention …
Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1
A Gastaldelli, M Gaggini… - Current Opinion in Clinical …, 2017 - journals.lww.com
The implications of these findings are very important for the management of type 2 diabetes
given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia …
given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia …
Cross-validation of a glucose-insulin-glucagon pharmacodynamics model for simulation using data from patients with type 1 diabetes
Background: Currently, no consensus exists on a model describing endogenous glucose
production (EGP) as a function of glucagon concentrations. Reliable simulations to …
production (EGP) as a function of glucagon concentrations. Reliable simulations to …
Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
DR Owens, L Monnier, GB Bolli - Diabetes & metabolism, 2013 - Elsevier
Metabolic consequences of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the
result of enhanced glucose-stimulated insulin secretion, inhibition of glucagon release …
result of enhanced glucose-stimulated insulin secretion, inhibition of glucagon release …
Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats
Y Cao, W Gao, WJ Jusko - Pharmaceutical research, 2012 - Springer
Purpose To provide a mechanism-based model to quantitatively describe GLP-1
pharmacokinetics (PK) and pharmacodynamics (PD) in rats. Methods Intravenous (IV) …
pharmacokinetics (PK) and pharmacodynamics (PD) in rats. Methods Intravenous (IV) …
[HTML][HTML] Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
M Lucey, P Pickford, S Bitsi, J Minnion, J Ungewiss… - Molecular …, 2020 - Elsevier
Objective The objective of this study was to determine how pharmacokinetically
advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias …
advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias …
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α-and β-cell function and …
Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2
diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative …
diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative …